Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2017, Article ID 6592139, 17 pages
https://doi.org/10.1155/2017/6592139
Review Article

TSPO PET Imaging: From Microglial Activation to Peripheral Sterile Inflammatory Diseases?

1CHRU Tours, 2 Boulevard Tonnellé, 37044 Tours, France
2Institut National de la Santé et de la Recherche Médicale U930, 10 Boulevard Tonnellé, 37032 Tours, France

Correspondence should be addressed to Bérenger Largeau; rf.sruot-vinu.ute@uaegral.regnereb

Received 26 May 2017; Revised 1 August 2017; Accepted 7 August 2017; Published 25 September 2017

Academic Editor: Anne Roivainen

Copyright © 2017 Bérenger Largeau et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. A. de Jesus, S. W. Canna, Y. Liu, and R. Goldbach-Mansky, “Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling,” Annual Review of Immunology, vol. 33, no. 1, pp. 823–874, 2015. View at Publisher · View at Google Scholar
  2. N. Raje and C. Dinakar, “Overview of immunodeficiency disorders,” Immunology and Allergy Clinics of North America, vol. 35, no. 4, pp. 599–623, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Sleasman, “The association between immunodeficiency and the development of autoimmune disease,” Advances in Dental Research, vol. 10, no. 1, pp. 57–61, 2016. View at Publisher · View at Google Scholar
  4. C.-J. Chen, H. Kono, D. Golenbock, G. Reed, S. Akira, and K. L. Rock, “Identification of a key pathway required for the sterile inflammatory response triggered by dying cells,” Nature Medicine, vol. 13, no. 7, pp. 851–856, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. K. L. Rock, E. Latz, F. Ontiveros, and H. Kono, “The sterile inflammatory response,” Annual Review of Immunology, vol. 28, pp. 321–342, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Zhang, J. Feng, J. Du et al., “Macrophage-derived IL-1α promotes sterile inflammation in a mouse model of acetaminophen hepatotoxicity,” Cellular & Molecular Immunology, 2017. View at Publisher · View at Google Scholar
  7. C. Ju and P. Mandrekar, “Macrophages and Alcohol-Related Liver Inflammation,” Alcohol Research: Current Reviews, vol. 37, pp. 251–262, 2015. View at Google Scholar
  8. B. T. Mossman and A. Churg, “Mechanisms in the pathogenesis of asbestosis and silicosis,” The American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 5, pp. 1666–1680, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. J. M. Craig, A. L. Scott, and W. Mitzner, “Immune-mediated inflammation in the pathogenesis of emphysema: insights from mouse models,” Cell and Tissue Research, vol. 367, no. 3, pp. 591–605, 2017. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Nuki and P. A. Simkin, “A concise history of gout and hyperuricemia and their treatment,” Arthritis Research and Therapy, vol. 8, supplement 1, article S1, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. H. L. Weiner and D. Frenkel, “Immunology and immunotherapy of Alzheimer's disease,” Nature Reviews Immunology, vol. 6, no. 5, pp. 404–416, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Gisterå and G. K. Hansson, “The immunology of atherosclerosis,” Nature Reviews Nephrology, vol. 13, no. 6, pp. 368–380, 2017. View at Publisher · View at Google Scholar
  13. K. C. Navegantes, R. Souza Gomes, P. A. T. Pereira, P. G. Czaikoski, C. H. M. Azevedo, and M. C. Monteiro, “Immune modulation of some autoimmune diseases: The critical role of macrophages and neutrophils in the innate and adaptive immunity,” Journal of Translational Medicine, vol. 15, no. 1, article 36, 2017. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Lech and H.-J. Anders, “Macrophages and fibrosis: how resident and infiltrating mononuclear phagocytes orchestrate all phases of tissue injury and repair,” Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1832, no. 7, pp. 989–997, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Freedman, J. Williams, and R. Bellamy, “Fever of unknown origin,” Clinical Medicine, vol. 8, no. 5, pp. 526–530, 2008. View at Publisher · View at Google Scholar
  16. D. A. Mankoff, “A definition of molecular imaging,” Journal of Nuclear Medicine, vol. 48, pp. 18N–21N, 2007. View at Google Scholar
  17. R. Kubota, S. Yamada, and K. Kubota, “Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography,” Journal of Nuclear Medicine, pp. 33–1972, 1992. View at Google Scholar
  18. T. Mochizuki, E. Tsukamoto, and Y. Kuge, “FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models,” Journal of Nuclear Medicine, vol. 42, pp. 1551–1555, 2001. View at Google Scholar
  19. S. Gogia, Y. Kaiser, and A. Tawakol, “Imaging High-Risk Atherosclerotic Plaques with PET,” Current Treatment Options in Cardiovascular Medicine, vol. 18, no. 12, 2016. View at Publisher · View at Google Scholar
  20. J. Bucerius, “Monitoring Vasculitis with 18F-FDG PET,” The Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 60, pp. 219–235, 2016. View at Google Scholar
  21. M. R. Dweck, C. Jones, N. V. Joshi et al., “Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis,” Circulation, vol. 125, no. 1, pp. 76–86, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. W. W. Lee, B. Marinelli, A. M. van der Laan et al., “PET/MRI of inflammation in myocardial infarction,” Journal of the American College of Cardiology, vol. 59, no. 2, pp. 153–163, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Wang, Q. Xie, and W. LV, “Positron emission tomography/computed tomography imaging and rheumatoid arthritis,” International Journal of Rheumatic Diseases, vol. 17, no. 3, pp. 248–255, 2014. View at Publisher · View at Google Scholar
  24. P. B. Shyn, “18F-FDG positron emission tomography: potential utility in the assessment of Crohn's disease,” Abdominal Imaging, vol. 37, no. 3, pp. 377–386, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Bernards, G. Pottier, B. Thézé, F. Dollé, and R. Boisgard, “In vivo evaluation of inflammatory bowel disease with the aid of μPET and the translocator protein 18 kDa radioligand [18F]DPA-714,” Molecular Imaging and Biology, vol. 17, pp. 67–75, 2014. View at Publisher · View at Google Scholar
  26. J. Bucerius, J. Schmaljohann, I. Böhm et al., “Feasibility of 18F-fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans - First results,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 4, pp. 815–820, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. I. E. Laitinen, P. Luoto, K. Nagren et al., “Uptake of 11C-Choline in Mouse Atherosclerotic Plaques,” Journal of Nuclear Medicine, vol. 51, no. 5, pp. 798–802, 2010. View at Publisher · View at Google Scholar
  28. C. M. Matter, “18F-Choline Images Murine Atherosclerotic Plaques Ex Vivo,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 3, pp. 584–589, 2005. View at Publisher · View at Google Scholar
  29. L. Tran, A. D. R. Huitema, M. H. van Rijswijk et al., “CD20 antigen imaging with 124I-rituximab PET/CT in patients with rheumatoid arthritis,” Human Antibodies, vol. 20, pp. 29–35, 2011. View at Google Scholar
  30. M. J. Uddin, B. C. Crews, K. Ghebreselasie et al., “Fluorinated COX-2 Inhibitors as Agents in PET Imaging of Inflammation and Cancer,” Cancer Prevention Research, vol. 4, no. 10, pp. 1536–1545, 2011. View at Publisher · View at Google Scholar
  31. D. Hartung, M. Schäfers, S. Fujimoto et al., “Targeting of matrix metalloproteinase activation for noninvasive detection of vulnerable atherosclerotic lesions,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, supplement 1, pp. S1–S8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. V. di Gialleonardo, A. Signore, A. W. J. M. Glaudemans, R. A. J. O. Dierckx, and E. F. J. de Vries, “N-(4-18F-fluorobenzoyl)interleukin-2 for PET of human-activated T lymphocytes,” Journal of Nuclear Medicine, vol. 53, no. 5, pp. 679–686, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. R. L. Wilder, “Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases,” Annals of the Rheumatic Diseases, vol. 61, supplement 2, pp. 96ii–99, 2002. View at Publisher · View at Google Scholar
  34. P. Lankinen, T. J. Mäkinen, T. A. Pöyhönen et al., “68Ga-DOTAVAP-P1 PET imaging capable of demonstrating the phase of inflammation in healing bones and the progress of infection in osteomyelitic bones,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 2, pp. 352–364, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Nahrendorf, E. Keliher, P. Panizzi et al., “18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis,” JACC Cardiovascular Imaging, vol. 2, no. 10, pp. 1213–1222, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Pugliese, O. Gaemperli, A. R. Kinderlerer et al., “Imaging of vascular inflammation with [11C]-PK11195 and positron emission tomography/computed tomography angiography,” Journal of the American College of Cardiology, vol. 56, no. 8, pp. 653–661, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Zavala, J. Haumont, and M. Lenfant, “Interaction of benzodiazepines with mouse macrophages,” European Journal of Pharmacology, vol. 106, no. 3, pp. 561–566, 1984. View at Publisher · View at Google Scholar · View at Scopus
  38. R. B. Banati, “Visualising microglial activation in vivo,” GLIA, vol. 40, no. 2, pp. 206–217, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. A.-C. Dupont, B. Largeau, M. J. S. Ribeiro, D. Guilloteau, C. Tronel, and N. Arlicot, “Translocator protein-18 kDa (TSPO) positron emission tomography (PET) imaging and its clinical impact in neurodegenerative diseases,” International Journal of Molecular Sciences, vol. 18, no. 4, article no. 785, 2017. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Awad and M. Gavish, “Binding of [3H]Ro 5–4864 and [3H]PK 11195 to Cerebral Cortex and Peripheral Tissues of Various Species: Species Differences and Heterogeneity in Peripheral Benzodiazepine Binding Sites,” Journal of Neurochemistry, vol. 49, no. 5, pp. 1407–1414, 1987. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Anzini, A. Cappelli, S. Vomero et al., “Molecular basis of peripheral vs central benzodiazepine receptor selectivity in a new class of peripheral benzodiazepine receptor ligands related to alpidem,” Journal of Medicinal Chemistry, vol. 39, no. 21, pp. 4275–4284, 1996. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Le Fur, M. L. Perrier, N. Vaucher et al., “Peripheral benzodiazepine binding sites: Effect of PK 11195, 1-(2-chlorophenyl)-n-methyl-n-(1-methylpropyl)-3-isoquinolinecarboxamide. I. In vitro studies,” Life Sciences, vol. 32, no. 16, pp. 1839–1847, 1983. View at Publisher · View at Google Scholar · View at Scopus
  43. F. Chauveau, H. Boutin, N. van Camp, F. Dollé, and B. Tavitian, “Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 12, pp. 2304–2319, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Chaki, T. Funakoshi, R. Yoshikawa et al., “Binding characteristics of [3H]DAA1106, a novel and selective ligand for peripheral benzodiazepine receptors,” European Journal of Pharmacology, vol. 371, no. 2-3, pp. 197–204, 1999. View at Publisher · View at Google Scholar · View at Scopus
  45. M.-R. Zhang, J. Maeda, K. Furutsuka et al., “[18F]FMDAA1106 and [18F]FEDAA1106: two positron-emitter labeled ligands for peripheral benzodiazepine receptor (PBR),” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 2, pp. 201–204, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. W. C. Kreisl, M. Fujita, Y. Fujimura et al., “Comparison of [11C]-(R)-PK 11195 and [11C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker,” NeuroImage, vol. 49, no. 4, pp. 2924–2932, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. A. A. Wilson, A. Garcia, J. Parkes et al., “Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors,” Nuclear Medicine and Biology, vol. 35, no. 3, pp. 305–314, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Selleri, F. Bruni, C. Costagli et al., “2-Arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides. New potent and selective peripheral benzodiazepine receptor ligands,” Bioorganic and Medicinal Chemistry, vol. 9, no. 10, pp. 2661–2671, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. D. R. Owen, A. J. Yeo, R. N. Gunn et al., “An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28,” Journal of Cerebral Blood Flow & Metabolism, vol. 32, pp. 1–5, 2012. View at Google Scholar
  50. K. K. Yoder, K. Nho, S. L. Risacher, S. Kim, L. Shen, and A. J. Saykin, “Influence of TSPO genotype on 11C-PBR28 standardized uptake values,” Journal of Nuclear Medicine, vol. 54, no. 8, pp. 1320–1322, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. Z. Fan, V. Calsolaro, R. A. Atkinson et al., “Flutriciclamide (18F-GE180) PET: First-in-human PET study of novel third-generation in vivo marker of human translocator protein,” Journal of Nuclear Medicine, vol. 57, no. 11, pp. 1753–1759, 2016. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Ikawa, T. G. Lohith, S. Shrestha et al., “11C-ER176, a radioligand for 18-kDa translocator protein, has adequate sensitivity to robustly image all three affinity genotypes in human brain,” Journal of Nuclear Medicine, vol. 58, no. 2, pp. 320–325, 2017. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Dessein, M. Chamaillard, and S. Danese, “Innate immunity in Crohnʼs disease,” Journal of Clinical Gastroenterology, vol. 42, pp. S144–S147, 2008. View at Publisher · View at Google Scholar
  54. D. Ellinghaus, J. Bethune, B.-S. Petersen, and A. Franke, “The genetics of Crohn's disease and ulcerative colitis-status quo and beyond,” Scandinavian Journal of Gastroenterology, vol. 50, no. 1, pp. 13–23, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Stefanelli, A. Malesci, A. Repici, S. Vetrano, and S. Danese, “New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets,” Current Drug Targets, vol. 9, no. 5, pp. 413–418, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. G. Solina, S. Mandalà, C. La Barbera, and V. Mandalà, “Current management of intestinal bowel disease: the role of surgery,” Updates in Surgery, vol. 68, no. 1, pp. 13–23, 2016. View at Publisher · View at Google Scholar · View at Scopus
  57. A. M. McCombie, R. T. Mulder, and R. B. Gearry, “How IBD patients cope with IBD: a systematic review,” Journal of Crohn's and Colitis, vol. 7, no. 2, pp. 89–106, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. F. Caobelli, L. Evangelista, N. Quartuccio et al., “Role of molecular imaging in the management of patients affected by inflammatory bowel disease: State-of-the-art,” World Journal of Radiology, vol. 8, no. 10, p. 829, 2016. View at Publisher · View at Google Scholar
  59. K. A. Chachu and M. T. Osterman, “How to diagnose and treat IBD mimics in the refractory IBD patient who does not have IBD,” Inflammatory Bowel Diseases, vol. 22, no. 5, pp. 1262–1274, 2016. View at Publisher · View at Google Scholar
  60. C. S. Gismera and B. S. Aladrén, “Inflammatory bowel diseases: a disease (s) of modern times? Is incidence still increasing?” World Journal of Gastroenterology, vol. 14, no. 36, pp. 5491–5498, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. D. Bettenworth, S. Reuter, S. Hermann et al., “Translational 18F-FDG PET/CT Imaging to Monitor Lesion Activity in Intestinal Inflammation,” Journal of Nuclear Medicine, vol. 54, no. 5, pp. 748–755, 2013. View at Publisher · View at Google Scholar
  62. P. Hindryckx, S. Staelens, L. Devisscher et al., “Longitudinal quantification of inflammation in the murine dextran sodium sulfate-induced colitis model using μpET/CT,” Inflammatory Bowel Diseases, vol. 17, no. 10, pp. 2058–2064, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. R. T. Lapp, B. J. Spier, S. B. Perlman, C. J. Jaskowiak, and M. Reichelderfer, “Clinical Utility of Positron Emission Tomography/Computed Tomography in Inflammatory Bowel Disease,” Molecular Imaging and Biology, vol. 13, no. 3, pp. 573–576, 2011. View at Publisher · View at Google Scholar
  64. D. A. Lemberg, R. M. Issenman, R. Cawdron et al., “Positron emission tomography in the investigation of pediatric inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 11, no. 8, pp. 733–738, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Löffler, M. Weckesser, C. Franzius, O. Schober, and K.-P. Zimmer, “High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease,” Annals of the New York Academy of Sciences, vol. 1072, pp. 379–385, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. R. S. Meisner, B. J. Spier, S. Einarsson et al., “Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 13, no. 8, pp. 993–1000, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Neurath, D. Vehling, K. Schunk et al., “Noninvasive assessment of Crohn's disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies,” The American Journal of Gastroenterology, vol. 97, no. 8, pp. 1978–1985, 2002. View at Publisher · View at Google Scholar
  68. J. Däbritz, N. Jasper, M. Loeffler, M. Weckesser, and D. Foell, “Noninvasive assessment of pediatric inflammatory bowel disease with 18F-fluorodeoxyglucose-positron emission tomography and computed tomography,” European Journal of Gastroenterology and Hepatology, vol. 23, no. 1, pp. 81–89, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. G. Treglia, N. Quartuccio, R. Sadeghi et al., “Diagnostic performance of Fluorine-18-Fluorodeoxyglucose positron emission tomography in patients with chronic inflammatory bowel disease: a systematic review and a meta-analysis,” Journal of Crohn's and Colitis, vol. 7, no. 5, pp. 345–354, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Katz, A. Eitan, Z. Amiri, and M. Gavish, “Dramatic increase in peripheral benzodiazepine binding sites in human colonic adenocarcinoma as compared to normal colon,” European Journal of Pharmacology, vol. 148, no. 3, pp. 483-484, 1988. View at Publisher · View at Google Scholar · View at Scopus
  71. K. Maaser, “Up-Regulation of the Peripheral Benzodiazepine Receptor during Human Colorectal Carcinogenesis and Tumor Spread,” Clinical Cancer Research, vol. 11, no. 5, pp. 1751–1756, 2005. View at Publisher · View at Google Scholar
  72. P. Grabowski, K. Maaser, and I. Schindler, “Overexpression of the peripheral benzodiazepine receptor is a relevant prognostic factor in stage III colorectal cancer,” Clinical Cancer Research, vol. 8, no. 10, pp. 3205–3209, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. M. A. Ostuni, L. Issop, G. Péranzi et al., “Overexpression of translocator protein in inflammatory bowel disease: potential diagnostic and treatment value,” Inflammatory Bowel Diseases, vol. 16, no. 9, pp. 1476–1487, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. D. H. Seo, X. Che, M. S. Kwak et al., “Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease,” Scientific Reports, vol. 7, no. 1, 2017. View at Publisher · View at Google Scholar
  75. C. J. Beltrán, L. E. Núñez, D. Díaz-Jiménez et al., “Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 16, no. 7, pp. 1097–1107, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. V. Papadopoulos, M. Baraldi, T. R. Guilarte et al., “Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function,” Trends in Pharmacological Sciences, vol. 27, no. 8, pp. 402–409, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Savino, N. Denora, R. M. Iacobazzi et al., “Synthesis, Characterization, and Cytotoxicity of the First Oxaliplatin Pt(IV) Derivative Having a TSPO Ligand in the Axial Position,” International Journal of Molecular Sciences, vol. 17, no. 7, 2016. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Liu, Y. Dou, R. Sun, Y. Zhang, and Y. Liu, “Molecular Mechanisms for Alcoholic Hepatitis Based on Analysis of Gene Expression Profile,” Hepatitis Monthly, vol. 15, no. 5, p. e27336, 2015. View at Publisher · View at Google Scholar
  79. L. Xie, J. Yui, A. Hatori et al., “Translocator protein (18 kDa), a potential molecular imaging biomarker for non-invasively distinguishing non-alcoholic fatty liver disease,” Journal of Hepatology, vol. 57, no. 5, pp. 1076–1082, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Hatori, J. Yui, L. Xie et al., “Utility of Translocator Protein (18 kDa) as a Molecular Imaging Biomarker to Monitor the Progression of Liver Fibrosis,” Scientific Reports, vol. 5, no. 1, 2015. View at Publisher · View at Google Scholar
  81. R. Fischer, M. Schmitt, J. G. Bode, and D. Häussinger, “Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells,” Gastroenterology, vol. 120, no. 5, pp. 1212–1226, 2001. View at Publisher · View at Google Scholar · View at Scopus
  82. E. Campioli, G. Carnevale, R. Avallone, D. Guerra, and M. Baraldi, “Morphological and receptorial changes in the epididymal adipose tissue of rats subjected to a stressful stimulus,” Obesity, vol. 19, no. 4, pp. 703–708, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. N. Wang, H. Liang, and K. Zen, “Molecular mechanisms that influence the macrophage M1-M2 polarization balance,” Frontiers in Immunology, vol. 5, article 614, 2014. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Capitanio, A. J. Nordin, A. R. Noraini, and C. Rossetti, “PET/CT in nononcological lung diseases: Current applications and future perspectives,” European Respiratory Review, vol. 25, no. 141, pp. 247–258, 2016. View at Publisher · View at Google Scholar · View at Scopus
  85. H. M. Branley, R. M. du Bois, A. U. Wells, and H. A. Jones, “PET scanning of macrophages in patients with scleroderma fibrosing alveolitis,” Nuclear Medicine and Biology, vol. 35, no. 8, pp. 901–909, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Goel and R. Gadiraju, “Diffuse lung uptake of 111in octreotide from chronic emphysema,” Journal of Nuclear Medicine Technology, vol. 41, no. 2, pp. 117-118, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. S. H. Saverymuttu, G. Phillips, A. M. Peters, and J. P. Lavender, “Indium 111 autologous leucocyte scanning in lobar pneumonia and lung abscesses,” Thorax, vol. 40, no. 12, pp. 925–930, 1985. View at Publisher · View at Google Scholar · View at Scopus
  88. H. A. Jones, S. Sriskandan, A. M. Peters et al., “Dissociation of neutrophil emigration and metabolic activity in lobar pneumonia and bronchiectasis,” European Respiratory Journal, vol. 10, no. 4, pp. 795–803, 1997. View at Google Scholar · View at Scopus
  89. E. Bribes, D. Carrière, C. Goubet, S. Galiègue, P. Casellas, and S. Joêlle, “Immunohistochemical Assessment of the Peripheral Benzodiazepine Receptor in Human Tissues,” Journal of Histochemistry & Cytochemistry, vol. 52, no. 1, pp. 19–28, 2016. View at Publisher · View at Google Scholar
  90. J. C. Mak and P. J. Barnes, “Peripheral type benzodiazepine receptors in human and guinea pig lung: characterization and autoradiographic mapping,” Journal of Pharmacology and Experimental Therapeutics, vol. 252, pp. 880–885, 1990. View at Google Scholar
  91. H. A. Jones, S. O. Valind, I. C. Clark et al., “Kinetics of lung macrophages monitored in vivo following particulate challenge in rabbits,” Toxicology and Applied Pharmacology, vol. 183, no. 1, pp. 46–54, 2002. View at Publisher · View at Google Scholar · View at Scopus
  92. L. Zuo, K. Lucas, C. A. Fortuna, C. Chuang, and T. M. Best, “Molecular regulation of toll-like receptors in asthma and COPD,” Frontiers in Physiology, vol. 6, article 312, 2015. View at Publisher · View at Google Scholar
  93. Y. Duan, M. Zhou, J. Xiao et al., “Prediction of key genes and miRNAs responsible for loss of muscle force in patients during an acute exacerbation of chronic obstructive pulmonary disease,” International Journal of Molecular Medicine, vol. 38, no. 5, pp. 1450–1462, 2016. View at Publisher · View at Google Scholar · View at Scopus
  94. Y. Chen and J. Qiao, “Protein-protein interaction network analysis and identifying regulation microRNAs in asthmatic children,” Allergologia et Immunopathologia, vol. 43, no. 6, pp. 584–592, 2015. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Becker, F.-N. Vögtle, D. Stojanovski, and C. Meisinger, “Sorting and assembly of mitochondrial outer membrane proteins,” Biochimica et Biophysica Acta - Bioenergetics, vol. 1777, no. 7-8, pp. 557–563, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. J. Gatliff, D. East, J. Crosby et al., “TSPO interacts with VDAC1 and triggers a ROS-mediated inhibition of mitochondrial quality control,” Autophagy, vol. 10, no. 12, pp. 2279–2296, 2015. View at Publisher · View at Google Scholar
  97. F. Li, J. Liu, N. Liu, L. A. Kuhn, R. M. Garavito, and S. Ferguson-Miller, “Translocator Protein 18 kDa (TSPO): An Old Protein with New Functions?” Biochemistry, vol. 55, no. 20, pp. 2821–2831, 2016. View at Publisher · View at Google Scholar · View at Scopus
  98. O. A. Jaffer, A. B. Carter, P. N. Sanders et al., “Mitochondrial-Targeted Antioxidant Therapy Decreases Transforming Growth Factor-β–Mediated Collagen Production in a Murine Asthma Model,” American Journal of Respiratory Cell and Molecular Biology, vol. 52, no. 1, pp. 106–115, 2015. View at Publisher · View at Google Scholar
  99. D. J. Rowlands, “Mitochondria dysfunction: a novel therapeutic target in pathological lung remodeling or bystander?” Pharmacology and Therapeutics, vol. 166, pp. 96–105, 2016. View at Publisher · View at Google Scholar · View at Scopus
  100. H. A. Jones, P. S. Marino, B. H. Shakur, and N. W. Morrell, “In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma,” European Respiratory Journal, vol. 21, no. 4, pp. 567–573, 2003. View at Publisher · View at Google Scholar · View at Scopus
  101. M. Gavish, S. Cohen, and R. Nagler, “Cigarette smoke effects on TSPO and VDAC expression in a cellular lung cancer model,” European Journal of Cancer Prevention, vol. 25, no. 5, pp. 361–367, 2016. View at Publisher · View at Google Scholar · View at Scopus
  102. H. M. Branley, R. M. du Bois, A. U. Wells, and H. A. Jones, “Peripheral-type benzodiazepine receptors in bronchoalveolar lavage cells of patients with interstitial lung disease,” Nuclear Medicine and Biology, vol. 34, no. 5, pp. 553–558, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. R. M. Silver, K. S. Miller, M. B. Kinsella, E. A. Smith, and S. I. Schabel, “Evaluation and management of scleroderma lung disease using bronchoalveolar lavage,” The American Journal of Medicine, vol. 88, no. 5, pp. 470–476, 1990. View at Publisher · View at Google Scholar · View at Scopus
  104. S. H. Audi, C. A. Dawson, S. B. Ahlf, and D. L. Roerig, “Lung tissue mitochondrial benzodiazepine receptors increase in a model of pulmonary inflammation,” Lung, vol. 180, no. 5, pp. 241–250, 2002. View at Publisher · View at Google Scholar · View at Scopus
  105. X. Qi, J. Xu, F. Wang, and J. Xiao, “Translocator protein (18 kDa): A promising therapeutic target and diagnostic tool for cardiovascular diseases,” Oxidative Medicine and Cellular Longevity, Article ID 162934, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. C. M. Weyand and J. J. Goronzy, “Medium- and Large-Vessel Vasculitis,” New England Journal of Medicine, vol. 349, no. 2, pp. 160–169, 2003. View at Publisher · View at Google Scholar
  107. FD. Carmona, P. Coit, G. Saruhan-Direskeneli et al., “Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy,” Scientific Reports, vol. 7, p. 43953, 2017. View at Publisher · View at Google Scholar
  108. FD. Carmona, SL. Mackie, J-E. Martín et al., “A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility,” American Journal of Human Genetics, vol. 96, pp. 565–580, 2015. View at Google Scholar
  109. G. Saruhan-Direskeneli, T. Hughes, K. Aksu et al., “Identification of Multiple Genetic Susceptibility Loci in Takayasu Arteritis,” American Journal of Human Genetics, vol. 93, pp. 298–305, 2013. View at Publisher · View at Google Scholar
  110. F. Lamare, R. Hinz, O. Gaemperli et al., “Detection and Quantification of Large-Vessel Inflammation with 11C-(R)-PK11195 PET/CT,” Journal of Nuclear Medicine, vol. 52, no. 1, pp. 33–39, 2010. View at Publisher · View at Google Scholar
  111. B. Seeliger, J. Sznajd, J. C. Robson et al., “Are the 1990 American College of Rheumatology vasculitis classification criteria still valid?” Rheumatology, vol. 56, no. 7, pp. 1154–1161, 2017. View at Publisher · View at Google Scholar
  112. A. Lekic, Z. Brekalo, A. Kvesic et al., “Cross-talk Between Enzymes Matrix-metalloproteinsese 2 and 9 and Regulatory T-cell Immunity in the Global Burden of Atherosclerosis,” Scandinavian Journal of Immunology, vol. 86, no. 1, pp. 65–71, 2017. View at Publisher · View at Google Scholar
  113. P. Libby, “Inflammation in atherosclerosis,” Nature, vol. 420, no. 6917, pp. 868–874, 2002. View at Publisher · View at Google Scholar · View at Scopus
  114. Q. Li, Y. Wang, H. Li, G. Shen, and S. Hu, “Ox-LDL influences peripheral Th17/treg balance by modulating treg apoptosis and Th17 proliferation in atherosclerotic cerebral infarction,” Cellular Physiology and Biochemistry, vol. 33, no. 6, pp. 1849–1862, 2014. View at Publisher · View at Google Scholar
  115. A. M. Lundberg and G. K. Hansson, “Innate immune signals in atherosclerosis,” Clinical Immunology, vol. 134, no. 1, pp. 5–24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. N. Sasaki, T. Yamashita, M. Takeda, and K.-I. Hirata, “Regulatory T cells in atherogenesis,” Journal of Atherosclerosis and Thrombosis, vol. 19, no. 6, pp. 503–515, 2012. View at Publisher · View at Google Scholar · View at Scopus
  117. J. M. W. Taylor, A.-M. Allen, and A. Graham, “Targeting mitochondrial 18 kDa translocator protein (TSPO) regulates macrophage cholesterol efflux and lipid phenotype,” Clinical Science, vol. 127, no. 10, pp. 603–613, 2014. View at Publisher · View at Google Scholar · View at Scopus
  118. L. Veenman, V. Papadopoulos, and M. Gavish, “Channel-like functions of the 18-kDA translocator protein (TSPO): Regulation of apoptosis and steroidogenesis as part of the host-defense response,” Current Pharmaceutical Design, vol. 13, no. 23, pp. 2385–2405, 2007. View at Publisher · View at Google Scholar · View at Scopus
  119. L. Veenman and M. Gavish, “The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development,” Pharmacology and Therapeutics, vol. 110, no. 3, pp. 503–524, 2006. View at Publisher · View at Google Scholar · View at Scopus
  120. S. Cuhlmann, W. Gsell, K. Van Der Heiden et al., “In vivo mapping of vascular inflammation using the translocator protein tracer 18F-FEDAA1106,” Molecular Imaging, vol. 13, no. 6, 2014. View at Publisher · View at Google Scholar · View at Scopus
  121. S. Hellberg, J. M. Silvola, M. Kiugel et al., “18-kDa translocator protein ligand 18F-FEMPA: biodistribution and uptake into atherosclerotic plaques in mice,” Journal of Nuclear Cardiology, vol. 24, no. 3, pp. 862–871, 2017. View at Publisher · View at Google Scholar
  122. O. Gaemperli, J. Shalhoub, and D. R. J. Owen, “Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography,” European Heart Journal, vol. 33, no. 15, pp. 1902–1910, 2012. View at Publisher · View at Google Scholar · View at Scopus
  123. G. Chinetti-Gbaguidi, M. Daoudi, M. Rosa et al., “Human Alternative Macrophages Populate Calcified Areas of Atherosclerotic Lesions and Display Impaired RANKL-Induced Osteoclastic Bone Resorption ActivityNovelty and Significance,” Circulation Research, vol. 121, no. 1, pp. 19–30, 2017. View at Publisher · View at Google Scholar
  124. J. Dimitrova-Shumkovska, L. Veenman, T. Ristoski, S. Leschiner, and M. Gavish, “Chronic high fat, high cholesterol supplementation decreases 18 kDa Translocator Protein binding capacity in association with increased oxidative stress in rat liver and aorta,” Food and Chemical Toxicology, vol. 48, no. 3, pp. 910–921, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. C. J. van der Laken, E. H. Elzinga, and M. A. Kropholler, “Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-(R)-PK11195 and positron emission tomography,” Arthritis & Rheumatism, vol. 58, no. 11, pp. 3350–3355, 2008. View at Publisher · View at Google Scholar · View at Scopus
  126. V. F. Derksen, T. W. Huizinga, and D. van der Woude, “The role of autoantibodies in the pathophysiology of rheumatoid arthritis,” Seminars in Immunopathology, vol. 39, no. 4, pp. 437–446, 2017. View at Publisher · View at Google Scholar
  127. E. S. Norli, G. H. Brinkmann, T. K. Kvien et al., “Self-limiting arthritis among patients fulfilling the 2010 ACR/EULAR classification criteria for rheumatoid arthritis in a very early arthritis cohort,” Seminars in Arthritis and Rheumatism, vol. 46, no. 3, pp. 272–278, 2016. View at Publisher · View at Google Scholar · View at Scopus
  128. X. Shao, X. Wang, S. J. English et al., “Imaging of carrageenan-induced local inflammation and adjuvant-induced systemic arthritis with [11C]PBR28 PET,” Nuclear Medicine and Biology, vol. 40, no. 7, pp. 906–911, 2013. View at Publisher · View at Google Scholar · View at Scopus
  129. Y. Y. J. Gent, K. Weijers, C. F. M. Molthoff et al., “Promising potential of new generation translocator protein tracers providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritis,” Arthritis Research and Therapy, vol. 16, no. 2, article R70, 2014. View at Publisher · View at Google Scholar · View at Scopus
  130. G. Pottier, N. Bernards, F. Dollé, and R. Boisgard, “[18F]DPA-714 as a biomarker for positron emission tomography imaging of rheumatoid arthritis in an animal model,” Arthritis Research & Therapy, vol. 16, no. 2, article R69, 2014. View at Publisher · View at Google Scholar · View at Scopus
  131. M. Politis, N. Lahiri, F. Niccolini et al., “Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington’s disease gene carriers,” Neurobiology of Disease, vol. 83, pp. 115–121, 2015. View at Publisher · View at Google Scholar
  132. L. Hamelin, J. Lagarde, G. Dorothée et al., “Early and protective microglial activation in Alzheimer's disease: A prospective study using 18F-DPA-714 PET imaging,” Brain, vol. 139, no. 4, pp. 1252–1264, 2016. View at Publisher · View at Google Scholar · View at Scopus
  133. B. Zinnhardt, T. Viel, L. Wachsmuth et al., “Multimodal imaging reveals temporal and spatial microglia and matrix metalloproteinase activity after experimental stroke,” Journal of Cerebral Blood Flow & Metabolism, 2015. View at Publisher · View at Google Scholar
  134. T. Notter, J. M. Coughlin, T. Gschwind et al., “Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia,” Molecular Psychiatry, 2017. View at Publisher · View at Google Scholar · View at Scopus
  135. P. Iversen, D. A. Hansen, D. Bender et al., “Peripheral benzodiazepine receptors in the brain of cirrhosis patients with manifest hepatic encephalopathy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 7, pp. 810–816, 2006. View at Publisher · View at Google Scholar
  136. E. Kurtys, J. Doorduin, U. L. M. Eisel, R. A. J. O. Dierckx, and E. F. J. de Vries, “Evaluating [11C]PBR28 PET for Monitoring Gut and Brain Inflammation in a Rat Model of Chemically Induced Colitis,” Molecular Imaging and Biology, vol. 19, no. 1, pp. 68–76, 2017. View at Publisher · View at Google Scholar · View at Scopus
  137. J. H. Vera, Q. Guo, J. H. Cole et al., “Neuroinflammation in treated HIV-positive individuals: A TSPO PET study,” Neurology, vol. 86, no. 15, pp. 1425–1432, 2016. View at Publisher · View at Google Scholar · View at Scopus
  138. J. Hannestad, J.-D. Gallezot, T. Schafbauer et al., “Endotoxin-induced systemic inflammation activates microglia: [11C]PBR28 positron emission tomography in nonhuman primates,” NeuroImage, vol. 63, no. 1, pp. 232–239, 2012. View at Publisher · View at Google Scholar · View at Scopus
  139. L. Beckers, D. Ory, I. Geric et al., “Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration,” Molecular Imaging and Biology. View at Publisher · View at Google Scholar
  140. C. Wu, X. Yue, L. Lang et al., “Longitudinal PET imaging of muscular inflammation using 18F-DPA-714 and 18F-alfatide II and differentiation with tumors,” Theranostics, vol. 4, no. 5, pp. 546–555, 2014. View at Publisher · View at Google Scholar · View at Scopus